To claim CE for this podcast, please access the activity via the eLearning center here. This offers CE for Pharmacists.
Learn from experts in the field of chronic inflammatory demyelinating polyneuropathy (CIDP). This CE podcast will discuss the classic presentation and pathophysiology, traditional therapies, the latest evidence for new and emerging therapies of CIDP, and key aspects of CIDP that pharmacists should know.
Claire Spahn, PharmD, MS, BCPS is a clinical pharmacist at Stanford Health Care in Stanford, California. Dr. Spahn received her BS(Pharm degree from Trinity College, Dublin, Ireland, her PharmD degree from Western University of Health Sciences in Los Angeles and an MS degree from University of Florida. She completed a PGY1 acute care pharmacy residency at Stanford Health Care, Stanford California. Dr. Spahn practices in specialty ambulatory care clinics including neurology and pharmacogenomics.
Neelam Goyal, MD is a Clinical Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine. She earned her medical degree at SUNY Downstate in Brooklyn, NY. Subsequently, she completed her neurology residency, which included a chief year, followed by a fellowship year in neurophysiology, specializing in neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital. Dr. Goyal focuses on the diagnosis, management, and electrophysiological testing of neuromuscular disorders, including SFEMG. Her expertise extends to immune-mediated disorders such as myositis, myasthenia gravis, CIDP, and vasculitis. Her research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.
The following person in control of this activity’s content has relevant financial relationships:
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
This CE activity expires on February 26, 2027
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
